Evolution of platinum resistance in high-grade serous ovarian cancer
- PMID: 21742554
- DOI: 10.1016/S1470-2045(11)70123-1
Evolution of platinum resistance in high-grade serous ovarian cancer
Abstract
High-grade serous ovarian cancers account for most ovarian-cancer mortality. Although this disease initially responds well to platinum-based chemotherapy, relapse and progression to chemotherapy resistance are frequently seen. Time to relapse after first-line therapy is a predictor of response to secondary platinum treatment: more than 12 months is associated with high chance of a secondary response, whereas relapses within 6 months generally indicate platinum resistance. In this Personal View we discuss whether patterns of response, relapse, and the development of drug resistance in high-grade serous ovarian cancers are related to distinct underlying molecular and cellular biological characteristics. In particular, we propose that rapid relapse with platinum-resistant disease is due to minor subpopulations of intrinsically resistant cancer cells at presentation.
Copyright © 2011 Elsevier Ltd. All rights reserved.
Similar articles
-
Association of Somatic Mutations of ADAMTS Genes With Chemotherapy Sensitivity and Survival in High-Grade Serous Ovarian Carcinoma.JAMA Oncol. 2015 Jul;1(4):486-94. doi: 10.1001/jamaoncol.2015.1432. JAMA Oncol. 2015. PMID: 26181259 Free PMC article.
-
Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.Lancet Oncol. 2015 Jan;16(1):87-97. doi: 10.1016/S1470-2045(14)71135-0. Epub 2014 Dec 4. Lancet Oncol. 2015. PMID: 25481791 Clinical Trial.
-
Correlation Between E-cadherin Immunoexpression and Efficacy of First Line Platinum-Based Chemotherapy in Advanced High Grade Serous Ovarian Cancer.Pathol Oncol Res. 2015 Apr;21(2):347-56. doi: 10.1007/s12253-014-9827-1. Epub 2014 Aug 11. Pathol Oncol Res. 2015. PMID: 25108408
-
Studying platinum sensitivity and resistance in high-grade serous ovarian cancer: Different models for different questions.Drug Resist Updat. 2016 Jan;24:55-69. doi: 10.1016/j.drup.2015.11.005. Epub 2015 Nov 26. Drug Resist Updat. 2016. PMID: 26830315 Review.
-
Mechanisms underlying acquired platinum resistance in high grade serous ovarian cancer - a mini review.Biochim Biophys Acta Gen Subj. 2019 Feb;1863(2):371-378. doi: 10.1016/j.bbagen.2018.11.005. Epub 2018 Nov 10. Biochim Biophys Acta Gen Subj. 2019. PMID: 30423357 Review.
Cited by
-
DNA Repair Protein HELQ and XAB2 as Chemoresponse and Prognosis Biomarkers in Ascites Tumor Cells of High-Grade Serous Ovarian Cancer.J Oncol. 2022 Mar 29;2022:7521934. doi: 10.1155/2022/7521934. eCollection 2022. J Oncol. 2022. PMID: 35392433 Free PMC article.
-
Discrete mixture modeling to address genetic heterogeneity in time-to-event regression.Bioinformatics. 2014 Jun 15;30(12):1690-7. doi: 10.1093/bioinformatics/btu065. Epub 2014 Feb 14. Bioinformatics. 2014. PMID: 24532723 Free PMC article.
-
Evolutionary perspectives, heterogeneity and ovarian cancer: a complicated tale from past to present.J Ovarian Res. 2022 Jun 3;15(1):67. doi: 10.1186/s13048-022-01004-1. J Ovarian Res. 2022. PMID: 35659345 Free PMC article. Review.
-
Overview of Tumor Heterogeneity in High-Grade Serous Ovarian Cancers.Int J Mol Sci. 2023 Oct 11;24(20):15077. doi: 10.3390/ijms242015077. Int J Mol Sci. 2023. PMID: 37894756 Free PMC article. Review.
-
Mitotic Exit Dysfunction through the Deregulation of APC/C Characterizes Cisplatin-Resistant State in Epithelial Ovarian Cancer.Clin Cancer Res. 2018 Sep 15;24(18):4588-4601. doi: 10.1158/1078-0432.CCR-17-2885. Epub 2018 Apr 13. Clin Cancer Res. 2018. PMID: 29653924 Free PMC article.
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
